


Rilematovir

Chemical Properties

CAS No. :	1383450-81-4
Formula:	C ₂₁ H ₂₀ ClF ₃ N ₄ O ₃ S
Molecular Weight:	500.92
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Rilematovir (JNJ-678) is an inhibitor of fusion protein with antiviral activity and low cytotoxicity. Rilematovir can be used in studies about respiratory syncytial virus treatment.
Targets(IC50)	EGFR,RSV
In vitro	Rilematovir is highly active against a number of RSV strains from both A and B subtypes, especially the A2 strain. The EC ₅₀ of HeLa cells is 460pM[1].
In vivo	Rilematovir efficiently suppresses established acute lower respiratory tract infection in the animals after oral treatment of neonatal lambs with Rilematovir, or with an equally active close analog[1].

Solubility Information

Solubility	DMSO: 58.5 mg/mL (116.79 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.99 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9963 mL	9.9816 mL	19.9633 mL
5 mM	0.3993 mL	1.9963 mL	3.9927 mL
10 mM	0.1996 mL	0.9982 mL	1.9963 mL
50 mM	0.0399 mL	0.1996 mL	0.3993 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Roymans D, et al. Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nat Commun. 2017 Aug 1;8 (1):167.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481